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Safety of Topical Corticosteroids in Pregnancy:
A Population-Based Cohort Study
Ching-Chi Chi1,2, Richard T. Mayon-White3 and Fenella T. Wojnarowska2
Topical corticosteroids may be indicated in pregnant women with skin conditions, but their safety in pregnancy is
unclear. We used the UK General Practice Research Database to conduct a population-based cohort study
to investigate whether maternal exposure to topical corticosteroids results in adverse pregnancy outcomes.
We identified 35,503 pregnant women prescribed topical corticosteroids during the period from 85 days before last
menstrual period (LMP) to delivery or fetal death and 48,630 unexposed women. We found no associations of
maternal exposure to topical corticosteroids with orofacial cleft (and its two subtypes, i.e., cleft lip ± palate (CLP)
and cleft palate alone (CP)), preterm delivery, and fetal death (including miscarriage and stillbirth). The findings were
similar when excluding exposure before LMP. In contrast, maternal exposure to potent/very potent topical
corticosteroids shortly before and during pregnancy was significantly associated with fetal growth restriction
(adjusted relative risk 2.08; 95% confidence interval 1.40–3.10; number needed to harm, 168), which was confirmed by
a significant dose-response relationship (P¼ 0.025) and the sensitivity analysis excluding exposure before LMP. The
increased risk for fetal growth restriction should be considered when prescribing potent/very potent topical
corticosteroids to pregnant women, and appropriate obstetric care should be provided.
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INTRODUCTION
Topical corticosteroids are prescribed to 46% of pregnant
women (Chi, 2009), but previous studies have given
conflicting evidence on the safety of corticosteroids in
pregnancy (Chi et al., 2009). One study found a significant
association between first-trimester use of topical corticoster-
oids and orofacial cleft (Edwards et al., 2003), whereas other
studies found no association (Czeizel and Rockenbauer,
1997; Ka¨lle´n, 2003; Pradat et al., 2003; Carmichael et al.,
2007). A study identified a significant association between
maternal use of very potent topical corticosteroids and
low birthweight (Mahe´ et al., 2007), but another study did
not find this (Mygind et al., 2002).
To investigate whether maternal exposure to topical
corticosteroids results in adverse pregnancy outcomes
including orofacial cleft, fetal growth restriction, preterm
delivery, and fetal death, we used the UK General Practice
Research Database (GPRD) to conduct a population-based
cohort study.
RESULTS
There were 39,857 pregnant women in data set 1: 13,365
exposed women (including 6,150 early exposed women) and
26,492 unexposed women. Data set 2 included 44,276
pregnant women (22,138 exposed and 22,138 unexposed).
The prevalences of potential confounders and indications for
topical corticosteroids in participants are summarized in
Table 1. There were a total of 53 (0.16%) orofacial cleft cases
including 23 (0.07%) cleft lip± palate (CLP) and 30 (0.09%)
cleft palate alone (CP) cases, 234 (0.59%) babies with fetal
growth restriction, 917 (2.30%) cases of preterm delivery,
and 3,627 (8.19%) fetal deaths including 3,523 (7.96%)
miscarriages and 104 (0.23%) stillbirths.
Orofacial cleft
No association of orofacial cleft with early maternal exposure
to topical corticosteroids (i.e., receiving one or more
prescriptions for topical corticosteroids during the period
from 85 days before last menstrual period (LMP) to
gestational week 12) was found (crude relative risk (RR)
1.13; 95% confidence interval (CI) 0.58–2.19; adjusted
RR 1.05; 95% CI 0.48–2.28; Table 2).
When stratified by corticosteroid potency, no associations
of orofacial cleft with exposure to mild/moderate and potent/
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very potent topical corticosteroids were found (adjusted
RR 0.82; 95% CI 0.31–2.13, and RR 1.19; 95% CI 0.42–3.39,
respectively).
The risk for orofacial cleft did not differ in women
prescribed various dosages of mild/moderate and potent/very
potent topical corticosteroids compared with the unexposed
group. When we ran the sensitivity analysis by limiting the
exposure period to the first 12 gestational weeks, the results
were not materially different (crude RR 1.14; 95% CI
0.48–2.68; adjusted RR 0.94; 95% CI 0.36–2.44).
The analyses on subtypes of orofacial cleft (CLP and CP)
and excluding syndromic cleft found no associations with
maternal exposure to topical corticosteroids (Supplementary
Tables S1 and S2 online).
Fetal growth restriction
Without stratification for potency, no association was found
between maternal exposure to topical corticosteroids and
fetal growth restriction (crude RR 1.17; 95% CI 0.90–1.53;
adjusted RR 1.10; 95% CI 0.80–1.50; Table 2). However, the
stratified analysis showed a significant association of fetal
growth restriction with maternal exposure to potent/very
potent topical corticosteroids (adjusted RR 2.08; 95% CI
1.40–3.10; Po0.001), but not with mild/moderate topical
corticosteroids (adjusted RR 0.85; 95% CI 0.59–1.21).
Furthermore, a significant difference in the risk for fetal
growth restriction was found between maternal exposure to
mild/moderate and potent/very potent topical corticosteroids
(Po0.001).
Table 1. Prevalences of potential confounders and indications for topical corticosteroids in participants
Data set 1 Data set 2
Exposed group
(n=13,365)
Unexposed group
(n=26,492) P-value
Exposed group
(n=22,138)
Unexposed group
(n=22,138) P-value
LE or antiphospholipid syndrome 39 (0.29%) 65 (0.25%) 0.3911 67 (0.30%) 43 (0.19%) 0.0221
Hypertensive disorder 358 (2.68%) 650 (2.45%) 0.1771 639 (2.89%) 549 (2.48%) 0.0081
Diabetes mellitus 213 (1.59%) 344 (1.30%) 0.0181 377 (1.70%) 243 (1.10%) o0.0011
Renal disease 77 (0.58%) 170 (0.64%) 0.4311 168 (0.76%) 145 (0.65%) 0.1921
Thyroid disorder 367 (2.75%) 580 (2.19%) 0.0011 693 (3.13%) 568 (2.57%) o0.0011
Cholestasis of pregnancy 2 (0.01%) 5 (0.02%) 0.7811 4 (0.02%) 2 (0.01%) 0.4141
HIV infection 2 (0.01%) 13 (0.05%) 0.0971
Asthma 1,738 (13.00%) 2,731 (10.31%) o0.0011
Thrombophilia 18 (0.08%) 10 (0.05%) 0.1301
Indication for topical corticosteroids
Autoimmune or pregnancy dermatosis 114 (0.85%) 66 (0.25%) o0.0011 82 (0.37%) 47 (0.21%) o0.0011
Steroid-responsive dermatosis 8,289 (62.02%) 3,397 (12.82%) 14,761 (66.68%) 4,715 (21.30%)
Nonsteroid-responsive dermatosis 1,043 (7.80%) 2,987 (11.28%) 3,872 (17.49%) 3,414 (15.42%)
Not recorded 3,919 (29.32%) 20,042 (75.65%) 3,423 (15.46%) 13,962 (63.07%)
Receiving US FDA pregnancy risk category
D or X drugs
4,590 (34.34%) 6,767 (25.66%) o0.0011 12,360 (55.83%) 10,857 (49.04%) o0.0011
Smoking
Never smoked 7,386 (55.26%) 14,845 (56.04%) 0.1622 11,606 (52.43%) 11,776 (53.19%) 0.0022
Smoker 3,612 (27.03%) 7,066 (26.67%) 6,756 (30.52%) 6,567 (29.66%)
Ex-smoker 2,155 (15.88%) 4,038 (15.24%) 3,217 (14.53%) 2,964 (13.39%)
Unknown 245 (1.83%) 543 (2.05%) 3.14 (2.53%) 831 (3.75%)
Length of follow-up in the children
(mean ± SD in years)
3.17±1.95 3.17±1.93 0.9643
Abbreviations: FDA, Food and Drug Administration; HIV, human immunodeficiency virus; LE, lupus erythematosus.
1The w2 test.
2The w2 test where the women with unknown habit were not included.
3Paired t-test.
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Table 2. Analyses of associations between topical corticosteroids and pregnancy outcomes
Stratified analysis
Adjusted RR (95% CI)
Events/
pregnancies Incidence
Crude RR
(95% CI) P-value
Adjusted RR
(95% CI) P-value
Mild/
moderate
corticosteroids P-value
Potent/very
potent
corticosteroids P-value
Orofacial cleft
Main analysis
Unexposed 42/26,492 0.16% 1 (referent) 1 (referent) 1 (referent) 1 (referent)
Early exposed 11/6,150 0.18% 1.13 (0.58–2.19) 0.722 1.05 (0.48–2.28)1 0.902 0.82 (0.31–2.13)1 0.679 1.19 (0.42–3.39)1 0.739
Sensitivity analysis
Unexposed 42/26,492 0.16% 1 (referent) 1 (referent) 1 (referent) 1 (referent)
Exposed (from LMP to
week 12)
6/3,331 0.18% 1.14 (0.48–2.68) 0.770 0.94 (0.36–2.44)1 0.897 0.66 (0.19–2.31)1 0.517 1.40 (0.39–4.99)1 0.600
Fetal growth restriction
Main analysis
Unexposed 147/26,492 0.55% 1 (referent) 1 (referent) 1 (referent) 1 (referent)
Exposed 87/13,365 0.65% 1.17 (0.90–1.53) 0.236 1.10 (0.80–1.50)2 0.562 0.85 (0.59–1.21)2 0.363 2.08 (1.40–3.10)2 o0.001
Sensitivity analysis
Unexposed 147/26,492 0.55% 1 (referent) 1 (referent) 1 (referent)
Exposed (from LMP to
delivery)
81/11,167 0.73% 1.31 (1.00–1.72) 0.052 1.22 (0.89–1.68)2 0.221 0.89 (0.61–1.29)2 0.528 2.78 (1.85–4.18)2 o0.001
Preterm delivery
Main analysis
Unexposed 614/26,492 2.32% 1 (referent) 1 (referent) 1 (referent) 1 (referent)
Exposed 303/13,365 2.27% 0.98 (0.85–1.12) 0.751 0.89 (0.76–1.05)2 0.164 0.86 (0.72–1.02)2 0.087 1.04 (0.82–1.33)2 0.736
Sensitivity analysis
Unexposed 614/26,492 2.32% 1 (referent) 1 (referent) 1 (referent) 1 (referent)
Exposed (from LMP to
delivery)
254/11,167 2.27% 0.98 (0.85–1.14) 0.799 0.91 (0.77–1.09)2 0.310 0.85 (0.70–1.02)2 0.085 1.16 (0.89–1.52)2 0.263
Miscarriage
Main analysis
Unexposed 2,006/22,138 9.06% 1 (referent) 1 (referent) 1 (referent) 1 (referent)
Exposed 1,517/22,138 6.85% 0.74 (0.69–0.79) o0.001 0.76 (0.70–0.82)3 o0.001 0.69 (0.63–0.76)3 o0.001 0.98 (0.87–1.09)3 0.656
Sensitivity analysis
Unexposed 2,006/22,138 9.06% 1 (referent) 1 (referent) 1 (referent) 1 (referent)
Exposed (from LMP to
delivery or fetal death)
1,108/18,293 6.06% 0.65 (0.60–0.70) o0.001 0.67 (0.61–0.73)3 o0.001 0.61 (0.55–0.67)3 o0.001 0.88 (0.77–0.99)3 0.041
Stillbirth
Main analysis
Unexposed 47/22,138 0.21% 1 (referent) 1 (referent) 1 (referent) 1 (referent)
Exposed 57/22,138 0.26% 1.21 (0.82–1.79) 0.327 1.43 (0.91–2.25)3 0.125 1.33 (0.80–2.21)3 0.268 1.68 (0.94–2.99)3 0.079
Sensitivity analysis
Unexposed 47/22,138 0.21% 1 (referent) 1 (referent) 1 (referent) 1 (referent)
Exposed (from LMP to
delivery or fetal death)
45/18,293 0.25% 1.16 (0.77–1.75) 0.480 1.48 (0.91–2.39)3 0.113 1.34 (0.78–2.29)3 0.286 1.71 (0.90–3.22)3 0.100
Abbreviations: CI, confidence interval; LMP, last menstrual period; RR, relative risk.
1Adjusted for hypertensive disorder, diabetes mellitus, renal disease, indication for topical corticosteroid, receiving US Food and Drug Administration (FDA)
pregnancy risk category D or X medicines, and smoking.
2Adjusted for lupus erythematosus, antiphospholipid syndrome, hypertensive disorder, diabetes mellitus, renal disease, thyroid disorder, cholestasis of
pregnancy, human immunodeficiency virus infection, asthma, indication for topical corticosteroid, receiving US FDA pregnancy risk category D or X
medicines, and smoking.
3Adjusted for lupus erythematosus, antiphospholipid syndrome, hypertensive disorder, diabetes mellitus, renal disease, thyroid disorder, thrombophilia,
cholestasis of pregnancy, indication for topical corticosteroid, receiving US FDA pregnancy risk category D or X medicines, and smoking.
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The RR for fetal growth restriction increased with the
dosage of potent/very potent topical corticosteroids
(P¼0.025), although the increase was small: a 0.01 increase
of the RR associated with every 10-g increase in the dosage
of potent/very potent topical corticosteroids. In contrast,
no dose-response relationship was found between mild/
moderate topical corticosteroids and fetal growth restriction
(P¼0.555) (Table 3).
When we ran the sensitivity analysis by excluding
exposure to topical corticosteroid before LMP, the association
between maternal exposure to potent/very potent topical
corticosteroids and fetal growth restriction remained signifi-
cant (adjusted RR 2.78; 95% CI 1.85–4.18; Po0.001).
There were 234 babies with fetal growth restriction, including
157 term and 77 premature babies. If we excluded the 77
premature babies, the association between potent/very potent
topical corticosteroid and fetal growth restriction remained
significant (adjusted RR 2.62; 95% CI 1.63–4.22; Po0.001).
Preterm delivery
No association between maternal exposure to topical
corticosteroids and preterm delivery was found (crude
RR 0.98; 95% CI 0.85–1.12; adjusted RR 0.89; 95%
CI 0.76–1.05; Table 2). The stratified analysis found no
associations of preterm delivery with exposure to either mild/
moderate or potent/very potent topical corticosteroids
(adjusted RR 0.86; 95% CI 0.72–1.02 and RR 1.04; 95%
CI 0.82–1.33, respectively).
No dose-response relationship between preterm delivery
and either mild/moderate or potent/very potent topical
corticosteroids was found (P¼0.853 and 0.132, respec-
tively). The results of the sensitivity analysis that excluded
exposure to topical corticosteroid before LMP were similar to
those of the main analysis.
Fetal death (miscarriage and stillbirth)
Maternal exposure to topical corticosteroids did not increase
the risk for miscarriage (crude RR 0.74; 95% CI 0.69–0.79;
adjusted RR 0.76; 95% CI 0.70–0.82) or stillbirth (crude RR
1.21; 95% CI 0.82–1.79; adjusted RR 1.43; 95% CI
0.91–2.25; Table 2).
The stratified analysis found no significantly increased risk
for miscarriage in women exposed to mild/moderate and
potent/very potent topical corticosteroids compared with the
unexposed group (adjusted RR 0.69; 95% CI 0.63–0.76, and
RR 0.98; 95% CI 0.87–1.09, respectively). No associations of
stillbirth with exposure to mild/moderate and potent/
very potent topical corticosteroids were found (adjusted
RR 1.33; 95% CI 0.80–2.21, and RR 1.68; 95% CI 0.94–2.99,
respectively). No substantial differences in the risk of mis-
carriage and stillbirth were found among women prescribed
various dosages of mild/moderate and potent/very potent
topical corticosteroids compared with the unexposed group.
DISCUSSION
Our study assessed the safety of topical corticosteroids
in pregnancy by considering orofacial cleft, fetal growth
restriction, preterm delivery, and fetal death. Data set 1 (with
a sample size of 6,150 early exposed and 26,492 unexposed
pregnancies) had a statistical power to detect a 2.26-fold
increase in the RR for orofacial cleft (a RR of X3 is generally
required for supporting teratogenicity of a drug; Khoury et al.,
1992) and provides substantial reassuring evidence of the
lack of association between topical corticosteroids and
orofacial cleft, which accords with most previous studies
(Czeizel and Rockenbauer, 1997; Ka¨lle´n, 2003; Pradat et al.,
2003; Carmichael et al., 2007). The only study showing an
association between maternal exposure to topical corticos-
teroids and orofacial cleft was a very small case–control study
(48 orofacial cleft cases and 58 controls) with a low response
rate (Edwards et al., 2003).
We found a significant association between fetal growth
restriction and maternal exposure to potent/very potent topical
corticosteroids before and during pregnancy (adjusted RR
2.08; 95% CI 1.40–3.10). The number needed to harm was
168, which means one additional fetal growth restriction for
every 168 pregnant women prescribed potent/very potent
topical corticosteroids. A significant dose-response relation-
ship was found (P¼0.025), although the magnitude
was relatively small. A 3% increase in the RR for fetal growth
restriction was associated with every 30-g increase (equivalent
to one regular tube) of potent/very potent topical corticoster-
oids prescribed. This finding is consistent with one small
cohort study showing a significant increase in low birthweight
children among women using very potent topical corticoster-
oids during pregnancy (Mahe´ et al., 2007). The RR for low
birthweight in relation to maternal use of very potent topical
corticosteroids was 2.84 (95% CI 1.07–7.54), which is similar
to our finding. In contrast, another cohort study did not find
similar associations in women exposed to either mild/
moderate or potent/very potent topical corticosteroids (Mygind
et al., 2002). However, the study did not consider dosage and
might thus have missed the association between potent/very
potent topical corticosteroids and fetal growth restriction.
Topical corticosteroids probably cause fetal growth
restriction by affecting the insulin-like growth factor system
that has a key role in mediating fetal growth and is implicated
in fetal growth restriction (Randhawa and Cohen, 2005).
Corticosteroids induce dysregulation of placental hormone/
cytokine gene expression and downregulation of the insulin-
like growth factor-II/Akt signaling pathway, which increase
placental apoptosis and lead to placental insufficiency and
fetal growth restriction (Ain et al., 2005). Furthermore,
significantly smaller placentas have been found in women
exposed to very potent topical corticosteroids during
pregnancy than in unexposed women (Mahe´ et al., 2007).
The increased risk for fetal growth restriction associated
with potent/very potent topical corticosteroids warrants app-
ropriate obstetric care. Fetal growth restriction has immediate
effects such as increased perinatal mortality, and increases
the risk of hypertension, type 2 diabetes, and metabolic
syndrome in adulthood (Barker et al., 1990, 1993). The ‘‘fetal
origin hypothesis’’ proposed that undernutrition in utero
results in metabolic adaptations of the fetus that lead
to cardiovascular and endocrine pathology in adulthood
(Barker, 1999).
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Table 3. Analyses of dose-response relationship between topical corticosteroids and pregnancy outcomes
Dosage of mild/moderate topical corticosteroids
Unexposed 10–30 g 31–60 g 61–100 g 4100 g P-value4
Orofacial cleft
Events/pregnancies 42/26,492 3/3,220 1/489 1/302 1/205
Incidence 0.16% 0.09% 0.20% 0.33% 0.49%
Adjusted RR (95% CI)1 1 (referent) 0.55 (0.16–1.90) 1.18 (0.15–9.12) 1.81 (0.23–14.00) 2.65 (0.34–20.69) 0.552
Fetal growth restriction
Events/pregnancies 147/26,492 40/7,549 8/1,623 1/753 4/681
Incidence 0.55% 0.53% 0.49% 0.13% 0.59%
Adjusted RR (95% CI)2 1 (referent) 0.90 (0.61–1.32) 0.82 (0.39–1.73) 0.21 (0.03–1.55) 0.96 (0.34–2.68) 0.555
Preterm delivery
Events/pregnancies 614/26,492 162/7,549 35/1,623 16/753 19/681
Incidence 2.32% 2.15% 2.16% 2.12% 2.79%
Adjusted RR (95% CI)2 1 (referent) 0.85 (0.70–1.03) 0.84 (0.59–1.21) 0.81 (0.49–1.36) 1.09 (0.68–1.77) 0.853
Miscarriage
Events/pregnancies 2,006/22,138 782/12,440 150/2,477 76/1,285 67/1,015
Incidence 9.06% 6.29% 6.06% 5.91% 6.60%
Adjusted RR (95% CI)3 1 (referent) 0.69 (0.63–0.76) 0.67 (0.56–0.80) 0.66 (0.52–0.84) 0.74 (0.57–0.96) 0.041
Stillbirth
Events/pregnancies 47/22,138 28/12,440 5/2,477 4/1,285 1/1,015
Incidence 0.21% 0.23% 0.20% 0.31% 0.10%
Adjusted RR (95% CI)3 1 (referent) 1.35 (0.79–2.31) 1.25 (0.47–3.29) 1.86 (0.64–5.40) 0.60 (0.08–4.43) 0.998
Dosage of potent/very potent topical corticosteroids
Unexposed 10–30 g 31–60 g 61–100 g 4100 g P-value4
Orofacial cleft
Events/pregnancies 42/26,492 3/1,359 1/247 1/476 0/287
Incidence 0.16% 0.22% 0.40% 0.21% 0%
Adjusted RR (95% CI)1 1 (referent) 1.26 (0.35–4.44) 2.30 (0.30–17.94) 1.18 (0.15–9.09) NA 0.478
Fetal growth restriction
Events/pregnancies 147/26,492 23/2,182 7/440 8/666 9/592
Incidence 0.55% 1.05% 1.59% 1.20% 1.52%
Adjusted RR (95% CI)2 1 (referent) 1.83 (1.12–2.99) 2.76 (1.24–6.16) 2.11 (0.99–4.47) 2.53 (1.23–5.22) 0.025
Preterm delivery
Events/pregnancies 614/26,492 58/2,182 12/440 17/666 16/592
Incidence 2.32% 2.66% 2.73% 2.55% 2.70%
Adjusted RR (95% CI)2 1 (referent) 1.05 (0.78–1.42) 1.08 (0.59–1.95) 0.99 (0.60–1.63) 1.04 (0.62–1.75) 0.132
Miscarriage
Events/pregnancies 2,006/22,138 331/4,000 60/779 105/1,141 83/972
Incidence 9.06% 8.28% 7.70% 9.20% 8.54%
Adjusted RR (95% CI)3 1 (referent) 0.96 (0.84–1.09) 0.89 (0.68–1.17) 1.08 (0.88–1.34) 0.99 (0.78–1.25) 0.069
Stillbirth
Events/pregnancies 47/22,138 14/4,000 3/779 4/1,141 4/972
Incidence 0.21% 0.35% 0.39% 0.35% 0.41%
Adjusted RR (95% CI)3 1 (referent) 1.65 (0.84–3.23) 1.80 (0.53–6.08) 1.56 (0.53–4.57) 1.85 (0.63–5.41) 0.998
Abbreviations: CI, confidence interval; NA, not available; RR, relative risk.
1Adjusted for hypertensive disorder, diabetes mellitus, renal disease, indication for topical corticosteroid, receiving US Food and Drug Administration (FDA)
pregnancy risk category D or X medicines, and smoking.
2Adjusted for lupus erythematosus, antiphospholipid syndrome, hypertensive disorder, diabetes mellitus, renal disease, thyroid disorder, cholestasis of
pregnancy, human immunodeficiency virus infection, asthma, indication for topical corticosteroid, receiving US FDA pregnancy risk category D or X
medicines, and smoking.
3Adjusted for lupus erythematosus, antiphospholipid syndrome, hypertensive disorder, diabetes mellitus, renal disease, thyroid disorder, thrombophilia,
cholestasis of pregnancy, indication for topical corticosteroid, receiving US FDA pregnancy risk category D or X medicines, and smoking.
4P-value reflects contribution of dosage of topical corticosteroids to the multivariate logistic regression model.
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Similar to previous studies (Mygind et al., 2002; Mahe´
et al., 2007), we found no association between maternal
exposure to topical corticosteroids and preterm delivery.
Data set 2 (22,138 exposed and 22,138 unexposed
pregnancies) had adequate power to detect a 1.08-fold
increase in the RR for fetal death in relation to exposure to
topical corticosteroids, and thus provides robust evidence
that exposure to topical corticosteroids does not increase the
risk for miscarriage and stillbirth.
Our study included pregnant women from the general
population and has a wide generalizability in estimating the
fetal effects of prescribing topical corticosteroids to pregnant
women.
Pregnant women may use topical corticosteroids for a
variable length of time after receiving the prescriptions. Thus,
women who commence using topical corticosteroids before
conception may stop or continue using them in pregnancy.
This situation makes measurement of exposure difficult,
which is mitigated in our study by including topical
corticosteroids prescribed before LMP for the main analyses
and then conducting sensitivity analyses after excluding
topical corticosteroids prescribed before LMP.
A particular strength of our study is the additional analyses
based on corticosteroid potency and dosage, which clarified
the association between exposure to potent/very potent
topical corticosteroids and fetal growth restriction by
showing a significant dose-response relationship.
Known confounding was minimized in our study. Con-
founding from maternal age and year of pregnancy was
controlled by matching; maternal disorder (hypertensive
disorder, diabetes mellitus, and so on), indication for topical
corticosteroid, exposure to Food and Drug Administration
(FDA) pregnancy risk category D and X medicines (i.e.,
medicines that may affect pregnancy outcomes), and smoking
were adjusted in statistical analysis. We did not adjust for
maternal drinking and body mass index because the quality
of data were unsatisfactory. We are unable to adjust for
socioeconomic factors as patient-level socioeconomic status
is not recorded in the GPRD; matching by general practice
was therefore used as a surrogate. Parity and paternal
height are not recorded in the GPRD and were thus not
controlled.
A limitation of our study is that the women’s adherence to
topical corticosteroids was unknown. If the exposed women
did not adhere to the prescribed corticosteroids, the fetal risk
would have been underestimated. Although there were no
studies on the adherence of pregnant women in the United
Kingdom, a study in the northern Netherlands showed a high
adherence of 94.5% to prescription drugs in pregnant women
(De Jong van den Berg et al., 1999).
Another limitation is the lack of knowledge about whether
the women had used over-the-counter topical corticosteroids
during pregnancy. Topical corticosteroids are predominantly
prescription-only medicines in the United Kingdom, except
hydrocortisone (the weakest corticosteroid) and clobetasone
butyrate (a moderate corticosteroid). The British National
Formulary and the instructions of the over-the-counter
preparations state that topical corticosteroids should not
be used in pregnancy without medical advice (Mehta, 2007).
In our study, prescriptions by general practitioners (GPs) were
assumed as the sole source of topical corticosteroids.
Orofacial cleft is classified as syndromic and nonsyndro-
mic clefts. Syndromic cleft occurs because of idiopathic,
inherited, or chromosomal defects, and presents with
associated congenital abnormalities. Nonsyndromic cleft is
believed to be the result of multifactorial environmental and
genetic factors with a low risk of familial occurrence
(Edwards et al., 2003). The family history of orofacial cleft
was not recorded in the GPRD and we thus could not
control for it. However, we did a sensitivity analysis that only
included nonsyndromic cleft and confirmed the lack
of association between maternal exposure to topical corti-
costeroids and nonsyndromic cleft.
As birthweight is not documented in the GPRD, we
defined fetal growth restriction as having a diagnosis for
small-for-dates, birthweight o10th percentile for gestational
age according to the Gairdner–Pearson chart (Gairdner and
Pearson, 1971), or birthweight o2,500 g in order to capture
as many cases as possible. The incidence of fetal growth
restriction in this study (0.59%) was lower than the reported
rate (3–7%) (Romo et al., 2009). The low incidence was the
result of under-reporting that may arise as birthweight is
recorded in the Red Book (Baby’s Health Record Book) and
not in the clinical records. The low number of fetal growth
restriction events could lead to loss of statistical power,
resulting in underestimation of the true effect and type II
error; i.e., a truly significant association is not detected.
However, our study has detected a significant association
between maternal exposure to potent/very potent topical
corticosteroids and fetal growth restriction. We assumed that
missed cases would have occurred equally in the exposed
and unexposed groups. The way that data are recorded in the
GPRD makes this a reasonable assumption.
GPs might be more likely to report adverse outcomes in the
exposed group because the exposed mothers had a higher
prevalence of diabetes, thyroid disease, asthma, and received
FDA category D and X drugs than the unexposed group
(Table 1). However, most of the differences were quite small.
The differences wereo1% in diabetes and thyroid disease, and
2.69% in asthma. Only the difference in receiving FDA category
D and X drugs was 8.68%. But we only observed a significant
increase in fetal growth restriction, but not in other adverse
outcomes such as orofacial cleft (which is related to drug use).
Implications
The results of this study provide reassuring evidence that there
is no increased risk of orofacial cleft, fetal death, and preterm
delivery in topical corticosteroid users. The findings do suggest
that there is an increased risk of fetal growth restriction that
should be taken into consideration when prescribing potent/
very potent topical corticosteroids to pregnant women.
Despite the association with fetal growth restriction,
potent/very topical corticosteroids may be the safer option
in treating inflammatory or autoimmune bullous dermatoses
in pregnancy when compared with oral corticosteroids,
ciclosporin, or azathioprine.
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MATERIALS AND METHODS
Data source
The GPRD has the primary-care records of over 3.5 million currently
registered patients (5.5% of the UK population) who are broadly
representative of the UK population (GPRD, 2007). Over 99% of the
UK population is registered with a GP through the National Health
Service (Gelfand et al., 2009). In the United Kingdom, all patients
are seen by their GP initially and most prescriptions are issued by the
GP rather than hospital or private practitioners. Patients’ data
including age, sex, smoking, drinking habit, diagnosis, referral to
hospitals, and prescriptions are automatically collected because the
participating GPs use their computers to record all medical details.
Hospital letters from specialists and discharge summaries are stored
in anonymized free text records. The quality and completeness of
the recorded data of the GPRD, including information on diagnoses
and treatments from specialists as well as pregnancy outcomes, have
been validated (Jick et al., 1991, 2003).
The GPRD assesses the quality of data recording by general
practices, and generates an up-to-standard date for each general
practice (GPRD, 2007). The up-to-standard indicates that the data
recording by the general practice has complied with specific quality
measures and the data are of adequate quality for epidemiological
research. The determination of the up-to-standard date is based upon
whether the completeness, continuity, and plausibility of data
recording in key areas meet the GPRD Recording Guidelines
(GPRD, 2007).
The GPRD has a specialized database of pregnant women and
their liveborn children, the Mother–Baby Link, which excludes
pregnancies ending in fetal death. We therefore utilized two data
sets: Data set 1 from the Mother–Baby Link from 2000 to 2006 used
for investigation of the associations of maternal exposure to topical
corticosteroids with orofacial cleft, fetal growth restriction, and
preterm delivery, and Data set 2 from the whole GPRD from 2000 to
2006 used for investigation of the association between maternal
exposure to topical corticosteroids and fetal death.
Participants
The participants in both data sets were pregnant women aged 15–44
years, who had registered with the practice for at least 6 months
before LMP, and had at least 6 months of up-to-standard follow-up
before LMP. Women with multifetal pregnancies were excluded.
The exposed group consisted of women having one or more
prescriptions for topical corticosteroids during the period from 85
days before LMP to delivery or fetal death. Women were excluded if
they were prescribed oral, injected, inhaled, ophthalmological,
or hemorrhoidal corticosteroids during the same period. Exposure
was defined as beginning at 85 days before LMP because women
may use topical corticosteroids for some time after receiving the
prescriptions. The critical period for the fusion of the lip and palate
(from the primary and second palates, respectively) is from the
gestational weeks 5 to 12 (Arosarena, 2007). In data set 1, the early
exposed group, limited to women who received one or more
prescriptions for topical corticosteroids during the period from
85 days before LMP to gestational week 12, was used when
analyzing orofacial cleft.
The unexposed group consisted of women not having prescrip-
tions for any corticosteroid preparations during the period from
85 days before LMP to delivery or fetal death. In data set 1, for each
exposed woman, up to two unexposed women were selected by
matching for maternal age (± 3 years), calendar year of pregnancy
(± 1 year), and general practice. In data set 2, for each exposed
woman, one unexposed woman was selected by matching for
maternal age (±1 year), calendar year of pregnancy (± 1 year), and
general practice.
Ascertainment of exposure
The prescription records were used to identify the timing, potency,
and dosage of topical corticosteroids prescribed. Topical corticos-
teroids were stratified into mild/moderate and potent/very potent
topical corticosteroids according to the British National Formulary
(Mehta, 2007). In the UK National Health Service, patients with a
skin condition are primarily managed by their registered general
practice. We reviewed the free text records of pregnant women who
had been referred to dermatologists to ensure that no unexposed
women were prescribed topical corticosteroids in hospitals.
Outcomes
1. Orofacial cleft. The two subtypes of orofacial cleft, i.e., CLP and
CP, were analyzed separately because they are etiologically
distinct (Stanier and Moore, 2004).
2. Fetal growth restriction (diagnosed as small-for-dates,
birthweight o2,500 g, or birthweight o10th percentile).
3. Preterm delivery (delivery before 37 completed weeks of gestation).
4. Fetal death and its two categories, miscarriage (early fetal
death before 24 completed weeks of gestation) and stillbirth
(late fetal death after 24 completed weeks of gestation)
(UK, 1992).
The diagnostic codes for identifying the outcomes are available
from the authors.
Statistical analysis
Paired t-test and w2 test were used to compare the prevalences of
potential confounders in the exposed and unexposed groups.
Univariate logistic regression was used to estimate the crude RRs
and 95% CIs for the outcomes in relation to exposure to topical
corticosteroids. Multivariate logistic regression with adjustment for
potential confounders (lupus erythematosus, antiphospholipid syn-
drome, hypertension, diabetes, renal disease, thyroid disorder,
thrombophilia, cholestasis of pregnancy, human immunodeficiency
virus infection, asthma, smoking, exposure to US FDA Pregnancy
Risk Categories D and X drugs (i.e., drugs that may affect
pregnancy outcomes), and indication for topical corticosteroids;
Wyszynski et al., 1997; Chung et al., 2000; Spilson et al., 2001;
Brodsky and Christou, 2004; Steer, 2005; Smith, 2006; Arosarena,
2007) was used to estimate the adjusted RRs and 95% CIs.
A stratified analysis was performed to calculate the adjusted RRs
and 95% CIs in relation to the potency of the topical corticosteroids.
When maternal exposure to topical corticosteroids of a particular
potency rank (i.e., mild/moderate or potent/very potent) was
significantly associated with an outcome, a covariate for the
corticosteroid potency was added in the multivariate logistic
regression model to test if there were significant differences in the
RR for the outcome between women exposed to mild/moderate
and potent/very potent topical corticosteroids.
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The dose-response relationship between the outcomes and
topical corticosteroids was examined by dividing the exposed group
into four subgroups according to the total dosage of prescribed
topical corticosteroids: 10–30 g, 31–60 g, 61–100 g, and4100 g. The
respective RRs and CIs for the outcomes in the four subgroups
compared with the unexposed group were calculated. A separate
multivariate logistic regression model with dosage as a continuous
variable was used to examine the dose-response relationship
between topical corticosteroids and the outcomes.
To test the robustness of our results, sensitivity analyses
excluding exposure before LMP were performed. The associations of
exposure to topical corticosteroids with orofacial cleft, CLP, and CP
were further examined by another sensitivity analysis excluding
syndromic cleft.
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